Share chart Artiva Biotherapeutics, Inc.
Extended chart
Simple chart
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. more details| IPO date | 2024-07-19 |
|---|---|
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.artivabio.com |
| Цена ао | 5.6 |
| Change price per day: | 0% (5.1) |
|---|---|
| Change price per week: | -3.95% (5.31) |
| Change price per month: | +27.18% (4.01) |
| Change price per 3 month: | -50.96% (10.4) |
| Change price per half year: | -53.42% (10.95) |
| Change price per year to date: | -49% (10) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.03977 | 17.09 | 1.54048 |
iShares Russell 2000 Growth ETF
|
0.00636 | 38.04 | 0.6026 |
| 0.03 | 27.57 | 1.07 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Fred Aslan M.D. | President, CEO & Director | 1975 (50 years) | |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor | 1974 (51 year) | |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer | 1975 (50 years) | |
| Mr. Christopher P. Horan | Chief Technical Operations Officer | 1967 (58 years) | |
| Ms. Neha Krishnamohan | CFO & Executive VP of Corporate Development | 1987 (38 years) | |
| Dr. Thorsten Graef M.D., Ph.D. | Chief Medical Officer | 1976 (49 years) | |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development | 1964 (61 year) | |
| Mr. Eugene Helsel | Senior Vice President of Regulatory Affairs | ||
| Dr. K. C Lim Pharm.D. | Senior Vice President of Clinical Operations |
Address: United States, San Diego, 5505 Morehouse Drive - open in Google maps, open in Yandex maps
Website: https://www.artivabio.com
Website: https://www.artivabio.com
